121
Views
3
CrossRef citations to date
0
Altmetric
Haematological Malignancy

t(8;16) AML developed subsequent to breast cancer therapy

, , , , &
Pages 153-155 | Published online: 04 Sep 2013

References

  • Srivastava A, Murari M, Datta NR. Early occurrence of acute myeloid leukemia following adjuvant radiotherapy and higher cumulative dose of cyclophosphamide in carcinoma breast. Indian J Cancer 2004;41:178–180.
  • Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004;101:1529–1536.
  • Bernasconi P, Orlandi E, Cavigliano P, Calatroni S, Boni M, Astori C, Pagnucco G, Giglio S, Caresana M, Lazzarino M, Bernasconi C. Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin’s lymphoma. Haematologica 2000;85: 1087–1091 .
  • Perot C, Huret JL. t(8;16)(p11;p 1 3). In: Atlas of genetics and cytogenetics in oncology and haematology [internet]. Updated December 1998. Available from http://www/infobiogen.fr/services/chromcancer/Anomalies/t0816.html.
  • Verma RS, Babu A. Tissue culture techniques and chromo-some preparation. In: Verma RS, Babu A, editors. Human chromosomes principles and techniques. 2nd ed. New York: Mc Graw-Hill, Inc. 1995. p 6–71.
  • Mitelman F. ISCN: An international system for human cytogenetic nomenclature. Basel: S Karger; 1995.
  • Ibrahim NK. Leukemogenic effect of chemotherapy in patients with breast carcinoma. Cancer 2004;101:1479–1481.
  • Weldon CB, Jaffe BM, Kahn MJ. Therapy-induced leukemias and myledysplastic syndromes after breast cancer treatment: An underemphasized clinical problem. Ann Surg Oncol 2002;9:738–744.
  • Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Chin Oncol 2005;23:4179–4191.
  • Park MJ, Park YH, Ahn HJ, Choi W, Paik KH, Kim JM, Chang YH, Ryoo BY, Yang SH. Secondary hematological malignancies after breast cancer chemotherapy. Leukemia Lymphoma 2005;46:1183–1188.
  • Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin—cyclophosphamide adjuvant therapy for operable breast cancer: The national surgical adjuvant breast and bowel project experience. J Chin Oncol 2003;21:1195–1204.
  • Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada clinical trials group. J Chin Oncol 2003;21:3066–3071.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.